Group One Trading’s VistaGen Therapeutics VTGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24K Buy
106,200
+74,900
+239% +$45.2K ﹤0.01% 5894
2026
Q1
$17.9K Sell
31,300
-12,700
-29% -$7.72K ﹤0.01% 6036
2025
Q4
$29.1K Sell
44,000
-32,300
-42% -$117K ﹤0.01% 6045
2025
Q3
$271K Sell
76,300
-38,200
-33% -$114K ﹤0.01% 4339
2025
Q2
$229K Buy
114,500
+113,000
+7,533% +$257K ﹤0.01% 4194
2025
Q1
$3.75K Sell
1,500
-22,400
-94% -$63.4K ﹤0.01% 6765
2024
Q4
$70.5K Buy
23,900
+400
+2% +$1.13K ﹤0.01% 4806
2024
Q3
$70.7K Sell
23,500
-225,200
-91% -$768K ﹤0.01% 4420
2024
Q2
$865K Sell
248,700
-38,200
-13% -$165K ﹤0.01% 2115
2024
Q1
$1.51M Sell
286,900
-269,600
-48% -$1.3M 0.01% 1721
2023
Q4
$2.86M Buy
556,500
+43,700
+9% +$165K 0.01% 1565
2023
Q3
$2.69M Buy
+512,800
New +$2.28M 0.01% 1395
2023
Q1
Sell
-413
Closed -$1.28K 8032
2022
Q4
$1.28K Sell
413
-10,770
-96% -$40.5K ﹤0.01% 6775
2022
Q3
$51K Buy
11,183
+6,586
+143% +$65.3K ﹤0.01% 5397
2022
Q2
$121K Buy
+4,597
New +$162K ﹤0.01% 4800

Other funds holding VTGN

Group One Trading's VTGN Position: Q2 2026 in Review

Group One Trading increased its VistaGen Therapeutics (VTGN) stake by 1,431% in Q2 2026, buying an estimated $172K and bringing the position to 304,385 shares worth $68.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5140.

Group One Trading first reported a position in VTGN in Q2 2022 and has held it in 13 quarters since. The position peaked at $395K in Q3 2023. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Group One Trading held 304,385 shares of VistaGen Therapeutics worth $68.8K as of Q2 2026.
  • Group One Trading bought 284,510 VistaGen Therapeutics shares in Q2 2026, an estimated $172K.
  • VistaGen Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #5140 holding.
  • Group One Trading first reported a position in VistaGen Therapeutics in Q2 2022 and has held it in 13 quarters since.
  • Group One Trading's VistaGen Therapeutics position peaked at $395K in Q3 2023.
  • 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.